key: cord-0931627-nczjk45a
authors: Shaath, Hibah; Alajez, Nehad M.
title: Identification of PBMC-based Molecular Signature Associational with COVID-19 Disease Severity
date: 2021-04-20
journal: Heliyon
DOI: 10.1016/j.heliyon.2021.e06866
sha: af3ce5ecd9e9efc282174ba875b48e6c6e9d0f0e
doc_id: 931627
cord_uid: nczjk45a

The longevity of COVID-19 as a global pandemic, and the devastating effects it has had on certain subsets of individuals thus far has highlighted the importance of identifying blood-based biomarkers associated with disease severity. We employed computational and transcriptome analyses of publicly available datasets from PBMCs from 126 patients with COVID-19 admitted to ICU (n=50), COVID-19 not admitted to ICU (n=50), non-COVID-19 admitted to ICU (n=16) and non-COVID-19 not admitted to ICU (n=10), and utilized the Gencode V33 assembly to analyze protein coding mRNA and long noncoding RNA (lncRNA) transcriptomes in the context of disease severity. Our data identified several aberrantly expressed mRNA and lncRNA based biomarkers associated with SARS-CoV-2 severity, which in turn significantly affected canonical, upstream, and disease functions in each group of patients. Immune, interferon, and antiviral responses were severely suppressed in COVID-19 admitted to ICU versus COVID-19 who were not admitted to ICU. Our data suggests a possible therapeutic approach for severe COVID-19 through administration of interferon therapy. Delving further into these biomarkers, roles and their implications on the onset and disease severity of COVID-19 could play a crucial role in patient stratification and identifying varied therapeutic options with diverse clinical implications.

Since its initial reporting [1, 2] and as the COVID-19 global pandemic reaches over 130 million confirmed cases and almost 3.0 million deaths to date [3] , increasing the need for efforts to be exerted to more comprehensively understand the etiology of this viral infection in all its strains, and the factors effecting disease severity. It has become apparent that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection does not affect all individuals in the same way, ranging from asymptomatic, to a dry cough, sore throat, fever, loss of taste or smell to more severe symptoms such as difficulty breathing or shortness of breath, requiring intensive care hospital facilities, and in some cases leading to fatality resulting from severe pneumonia in 10-15% of patients, acute respiratory distress (ARDS), multi-organ failure (MOF) and intravascular coagulopathy [4] .

According to early epidemiological studies, the most credible indicator of COVID-19 disease severity is age, as well as pre-existing conditions such as diabetes, hypertension and cardiovascular diseases. Such factors indicate that high risk groups are likely to possess biomarkers associated with unhealthy lifestyles and biological age, rather than chronological age [5] . To date, the molecular basis of severe COVID-19 symptoms are not well understood. Our previous studies have highlighted an important role for interferon and inflammatory response in COVID-19 [6] , as well as preferential induction of chemotaxis and lipid synthesis by SARS-CoV-2 [7] . Further studies into transcriptome analysis of coding and non-coding elements, as well as convalescent blood samples of both severe and mild cases of COVID-19 should aid in identifying molecular risk factors in order to be able to predict highly susceptible individuals for severe COVID-19 infection for early intervention and tailored therapy options.

Multiple studies have identified several biomarkers which could be potentially utilized in risk stratification models for predicting severe and fatal COVID-19. Biomarkers associated with cardiac and muscle injury as well as lower enzymes were found to be significantly elevated in severe and fatal case of COVID-19 [8] . Elevated levels of IL-6 and serum ferritin in nonsurvivors compared to survivors in addition to elevated C-reactive protein (CRP) could partially account for the observed inflammatory response in COVID-19, that when over reactive, can lead to cytokine storms which can cause acute lung injury and sepsis, in concordance with our observation of inflammatory cytokines correlating with severe cases of COVID-19 [6, 9, 10] .

Other studies reported thrombocytopenia to be associated with severe COVID-19. Low levels of platelet numbers was also characteristic of higher disease severity during the SARS outbreak, occurring in up to 55% of patients with it being a significantly high risk factor for mortality [11] .

Low platelet count, along with hypoxemia, have since been used by Zou et al for the development of a SARS prognostic tool with 96.2 accuracy [12] . Thirty one other observational studies involving 7613 participants, 25 of them describing the association between severe COVID-19 and low platelet counts revealing a lower platelet count in severe patients than nonsevere patients. Non-survivors of COVID-19 had much lower platelet counts than those that survived [13] .

Jiang et al showing a significant decrease in CD3+ T cells, CD4+ T cells, CD8+ T cells, and natural killer cells in severe cases admitted to the ICU compared with mild to moderate cases [14] as it has been confirmed that T cell immune responses play a vital role in recovery from SARS-Cov-2 infection, while Tregs may not play a crucial role in recovery [14, 15] . In another study by Zhao et al., RANTES (CCL5) chemokine was elevated in mild, but not severe cases of J o u r n a l P r e -p r o o f COVID-19. In contrast, IL-10 and IL-1RA were significantly upregulated in severe cases.

Cytokines typically associated with cytokines storms such as IL-6 and IFN-γ were only found to be significantly elevated in later stages of severe infection, implying cytokine storms arise as the result of severe cases of COVID-19 infection rather than their cause [16] . In addition to this, another study shows 14 other cytokines to be significantly elevated in COVID-19 patients, with varying expression profiles depending on case severity. Specifically, five of these, including IP-10, MCP-3, HGF, MIG, MIP-1a, and IL-1ra were found to play a significant role in disease severity and disease progression, where levels of these markers were remarkably higher in those critically ill and with an eventual fatal outcome [17] .

D-dimers concentrations can be detected in the blood post blood clot degradation, usually indicating thrombotic disorders or intravascular coagulation [18] . Several studies have since indicated D-dimer elevations in 3.75-68.0% of COVID-19 patients [10, 19, 20] . Yao et al., underwent an extensive clinical, laboratory, and radiological analysis of the characteristics of 248 cases of COVID-19 in Renmin Hospital of Wuhan University, Wuhan, China, in which they show D-dimer levels upon admission to correlate with disease severity, making it a reliable prognostic marker for in-hospital mortality [21] . Further research into the mechanisms and specificity of D-dimers in association with SARS-CoV-2 infection need to be further explored.

We previously describe the fundamental roles of long non-coding RNAs (lncRNAs) in their roles in several cellular processes. These can include the onset and progression of different diseases such as cancers and infectious disease [22, 23] . We described multiple expressed lncRNAs that were differentially expressed during the course of infection, which could serve as disease biomarkers for SARS-CoV-2 and other viral infections. Such lncRNAs including MALAT1 and NEAT1 were found to promote HIV-1 transcription and infection and promoting inflammatory J o u r n a l P r e -p r o o f mediated cell death respectively [24, 25] . Further investigation into these lncRNAs and other identified in the context of SARS-CoV-2 infection may provide valuable indication on novel methods of managing and preventing future global crises such as the pandemic we face today.

In recent weeks, many countries, particularly in Europe and the USA, have experienced a second wave of high numbers in COVID-19 infections, resulting in the spike seen worldwide. A recent study shows, and as hypothesized by the WHO, that there is no clear evidence to claim that this seasons weather or climate has a great influence on COVID-19 transmission in the most prominent urban cities in the UK [26] . On the 8 th December 2020, the first Pfizer/BioNTech vaccine was administered outside of clinical trials, and up to 4 million more are expected to receive it by the end of 2020, prioritizing the elderly and health care staff [27] . With the emergence of this new vaccine, new and valuable data will be obtained on its efficiency, however this will still be limited to COVID-19, highlighting the importance of studies such as the current one for a more in depth understanding of such viral infections with the hope of preventing further global pandemics in the near future.

In our current study, we utilized computational and transcriptome analyses of publicly available datasets PBMCs from 126 patients with COVID-19 admitted to ICU (n=50), COVID-19 not admitted to ICU (n=50), non-COVID-19 patients admitted to ICU (n=16) and non-COVID-19

patients not admitted to ICU (n=10) to analyze protein coding mRNA and lncRNA transcriptome. In-depth computational analysis employing ingenuity pathway analysis (IPA) tool shed some light onto mechanistic alterations in immune portrait from severe vs mild COVID-19.

We identify severely suppressed immune, interferon, and antiviral responses in COVID-19 patients admitted to ICU in comparison to COVID-19 cases which were not admitted to ICU.

The identification of mRNA-based and lncRNA-based biomarkers may enable significant J o u r n a l P r e -p r o o f discrimination between milder cases and those that have significant risks of fatality. This dataset is unique in that it utilizes several subsets of patients, highlighting differences in their response, so that we may make a comprehensive comparison for novel findings. Further investigation could potentially identify several factors to be included in risk stratification models.

The data in this study was acquired in the original study from Albany Medical Center in Albany, NY, where 126 blood samples from adult patients were acquired, as reported by Overmyer et al. [28] . Patient symptoms ranged from moderate to severe respiratory issues suspected of infection with SARS-CoV-2. One hundred patients tested positive and 26 of those tested were negative for COVID-19. Subjects were mainly of the senior population, with median age of 63. All blood samples were collected upon admission which involved the drawing quantities for two plasma preparation tubes (PPT) tubes. One tube, used for Leukocyte RNA sequencing, was processed through LeukoLOCK® filters, RNA was then eluted from LeukoLOCK filters following manufacturer recommendation, and samples were stored at -80•C for later analyses. For more details, please refer to the original paper by Overmyera et al, [28] .

Raw RNA sequencing data were retrieved from the sequence read archive (SRA) database under accession no. (PRJNA660067) [28] . Detailed experimental procedures are explained in the aforementioned reference. In brief, the TruSeq Stranded mRNA kit was used for library preparation. Paired-end (2x50bp) sequencing was conducted on an Illumina NovaSeq6000 sequencer. Pair-end FASTQ files were retrieved using the SRA toolkit version 2.9.2 as J o u r n a l P r e -p r o o f previously described [33] . FASTQ files were subsequently mapped and aligned to the Gencode V33 assembly (both protein coding and non-coding RNAs) using KALLISTO 0.42.1 as described before [29, 30] . Normalized expression data (TPM (Transcripts Per Million) mapped reads) were sequentially imported into AltAnalyze v.2.1.3 software for differential expression analysis using 2.0-fold change and adjusted <0.05 p-value cut-off. The Benjamini-Hochberg method was used to adjust for false discovery rate (FDR), while ANOVA analysis was used for all group comparisons. Transcripts were excluded from analysis based on TPM (< 1.0 raw expression value). Hierarchical clustering was performed using cosine for columns and cosine for rows, and marker finder prediction as detailed previously [29, 31] .

Ingenuity Pathways Analysis (IPA) software (Ingenuity Systems; www.ingenuity.com) was used to analyze differentially expressed genes thorough functional annotations and regulatory network analysis using upstream regulator analysis (URA). This platform analyzes upstream molecules connected to genes in the dataset through direct or indirect relationships based on changes in expression. Mechanistic networks (MN) analysis was employed by IPA to generate signaling cascades that connect upstream regulators which helps to visualize how they connect in order to explain the observed changes in gene expression. Biological processes and disease functions casually affected by the deregulation of genes in datasets can be identified via Downstream effector analysis (DEA), in addition to predictions on their activation state (Z score). IPA uses precise algorithms to predict functional regulatory networks from gene expression data and provides a significance score for each network according to the fit of the network to the set of focus genes in the database. The possibility that focus genes in the network are found together by chance is displayed as the p-value (negative log of P). The visualization of J o u r n a l P r e -p r o o f differentially affected cellular processed and pathways under various pathological conditions is made possible via the comparison analysis feature in IPA. Affected functional categories and pathways exhibiting ≥ 2.0 Z score (absolute) and p < 0.05 in at least one of the conditions were considered significant and were retained.

Microsoft excel 2016 and GraphPad Prism 8.0 software (GraphPad, San Diego, CA, USA) were used for statistical analyses and graphing. Two tailed t-test was used for comparative groups.

Benjamini-Hochberg method was used to adjust for false discovery rate (FDR) of transcriptome data, while ANOVA analysis was used for group comparisons. Adjusted p-values ≤ 0.05 were considered significant. For IPA analyses, a Z score (−2.0 ≥ Z ≥ 2.0) was considered significant.

Computational and transcriptome analyses of PBMCs from 126 patients with COVID-19 admitted to ICU (n=50), COVID-19 not admitted to ICU (n=50), non-COVID-19 patients admitted to ICU (n=16) and non-COVID-19 patients not admitted to ICU (n=10) were analyzed employing the marker discovery algorithm and data retrieved from the original study by Overmyera et al., [28] . Hierarchical clustering depicted putative markers associated with each of Figure 3 represents the COVID/ICU versus the COVID/non-ICU group and shows decreasing activation states for functions such as cellular movement, cellular growth and survival, inflammatory response, immune cell trafficking (Fig. 3a) , which includes suppressed activation, migration, chemotaxis, adhesion and transmigration (fig 3b) . Figure 3c shows those functions found to be activated (orange) in COVID/ICU versus the COVID/non-ICU which represent those related to infectious diseases such as replication, infectivity and viral entry.

RNA-seq and MarkerFinder analysis also revealed several differentially expressed markers which could serve as indicators of COVID-19 severity. Those transcripts were enriched in COVID-19 patients admitted to ICU compared to all other groups include AMPH, ARG1, ARMC12, ASPH, C5orf30, CD24, CSGALNACT1, DAAM2, FKBP5, GRB10, IL1R1, IL1R2, IRAK3, IRS2, OLAH, SAP30, TPST1 and ZBTB16 (Fig.4a and supplementary table 9 ). GZMH, GNLY, PRF1, LGALS2, SIGLEC1, KLRG1, KLRK1, XAF1, IFI27, IFI44L, and USP18. All data is represented as violin lots and have ANOVA p value of <0.001 (Fig.4b) .

Our data also highlighted lncRNA based biomarkers associated with SARS-CoV-2 severity. Our Upon further investigation on an individually selected lncRNA level, some lncRNA genes were significantly enriched in the COVID-19/ICU, while some were enriched in the COVID-19/non-ICU group (Fig 5c and 5d) . 

As the COVID-19 pandemic has surpassed an entire year of global devastation, it becomes more apparent that this will be an ongoing struggle with countless cases of progression towards severe and fatal forms of this illness. The urgent need for identification of clinical and laboratory indictors for these cases is imperative in classifying potential biomarkers for disease severity, diagnosis and therapy options. We extracted data from Overmyera et al., acquired from 126 patients with COVID-19 admitted to ICU (n=50), COVID-19 not admitted to ICU (n=50), non-COVID-19 patients admitted to ICU (n=16) and non-COVID-19 patients not admitted to ICU (n=10) [28] and went onto utilizing Gencode V33 assembly to analyze protein coding mRNA and lncRNA transcriptomes in these samples. Hierarchical clustering identified putative markers J o u r n a l P r e -p r o o f associated with each pathological condition employing the marker discovery algorithm highlighting the COVID-19 cases in need of ICU care to be enriched for gene ontologies associated with ion transmembrane transport. The general hypothesis is that ion currents play an important role in governing SARS-CoV-2 virion entry via host-membrane fusion, with Ca 2+ ions being necessary in promoting fusion peptide insertion into the lipid bilayer and the endocytosis pathway [32] . Previous work on SARS-CoV and MERS-CoV show Ca 2+ to be important for stimulating the fusogenic activity of the SARS-CoV fusion peptide and enhancing viral infection by approximately two-fold, respectively [33, 34] . This process entails the rearrangement of lipid bilayers further increasing Ca 2+ presence [35] . In fact, studies have shown amiodarone (a Ca 2+ ion channel blocker) to inhibit the spread of SARS-CoV in vitro [36] . Our recent studies have also shown preferential induction of lipid synthesis by SARS-CoV-2 [7] , further promoting the notion of lipid rearrangements that could affect ion transmembrane transport, cellular responses to peptide hormone stimulus and inositol lipid-mediated signaling as indicated by our GO analysis.

For the same group (COVID-19/ICU), a significant downregulation in immune response and defense response to the virus is observed in the majority of cases, plausibly responsible for the progression into severe infection experienced by these patients. Antigen receptor mediated signaling was also suppressed, which could be owed to the apparent downregulation of the gene expression coding angiotensin-converting enzyme 2 (ACE2), the antigen facilitating the entry of SARS-CoV and SARS-CoV-2, reported in some studies, with additional cardiovascular consequences associated with ACE2 downregulation [37] [38] [39] .

Comparing cases with severe symptoms requiring ICU care with COVID cases that did not require ICU, many conical pathways, upstream regulators and disease functions were affected, by either being activated or suppressed. Multiple conical pathways were found to be suppressed in ICU compared to non-ICU cases such as; natural killer (NK) cell signaling. Natural killer cells play an important role in generating an effective immune response to infection. Other studies have also highlighted NK cells to be significantly reduced in cases of severe infection compared to patients with mild infection and healthy individuals. This study suggests the use of cancer therapy drugs such as Monalizumab, as well as interferon α, chloroquine, and other antiviral agents in order to inhibit NKG2A, which restores the function of NK cells in cancers, and could also benefit those with severe cases of COVID-19 [40] . Another study also reported on depleted levels of NK cells in peripheral blood upon sudden deterioration due to COVID-19. Evidence has also shown that once patients have recovered from serious bouts of COVID-19 after therapy, NK cells numbers were restored with reduced expression of NKG2A, confirming NK cells to play a crucial role in disease severity [41] . Wilk with insufficient interferon responses causing immune deficiency and inability to fight the viral infection, whereas an increased interferon response and hyper-inflammation contributes to 'cytokine storms', leading to organ injury and sepsis [44] . Further research into the precise roles played by different interferons on their consequential responses needs to be further clarified in the context of COVID-19 disease progression and severity for the development of effective therapeutic options going forward.

In a previous study, we described the lncRNA transcriptional landscape in SARS-CoV-2 infected bronchial epithelial cells and identified a potential role for lncRNAs to be used as possible biomarkers during the course of infection. Our current study further identified aberrantly expressed lncRNAs in relation to different disease severities, where lncRNA genes were found to be enriched in the COVID-19/ICU group compared to non-ICU patients. Recently, there have been reports on the implications lncRNAs may have in the regulation of NLRP3 inflammasome and IL-6-assocciated inflammatory signaling in COVID-19, in association with several pathways like JAK/STAT, NF-κB, HIF-1α, and MAPK [45] . Nuclear enriched abundant transcript 1 (NEAT1) often reported as an oncogenic lncRNA, has been described to translocate from the nucleus to the cytoplasm to inflammasome assembly, thereby activating caspase 1 inducing inflammatory cytokine release [25] . LncRNA metastasis associated lung adenocarcinoma transcript 1 (MALAT1) has been described in several cancer types including breast [46] , pancreatic [47] , and lung adenocarcinoma [48] , and has additionally been associated with inflammation responses and cytokine secretion, especially IL-6, promoting tissue damage [49] .

Further research into the precise roles plays by different lncRNAs and how their expression J o u r n a l P r e -p r o o f affects the onset and severity of COVID-19 is needed to further clarify the precise roles played, which requires larger datasets and functional studies.

Expanding our understanding on what causes severe implication upon SARS-Cov-2 infection, and which factors differentiate these individuals from milder cases is highly important for more personalized, tailored prevention and treatment measures. The convenience of blood-based biomarkers associated with severity is valuable in identifying those at risk of severe symptoms leading to fatality. Our data contributes to our understanding of the internal environment in terms of differential mRNA and lncRNA expression, as well as the predicted consequences of these expression profiles with regards to affected canonical and upstream pathways related to COVID-19 infection. Further research into specific biomarkers and their implications need to be explored functionally and clinically for our continued perusal of biomarker identification and therapeutic utilization. 

A pneumonia outbreak associated with a new coronavirus of probable bat origin

A new coronavirus associated with human respiratory disease in China

Coronavirus disease (COVID-19) pandemic

Which lessons shall we learn from the 2019 novel coronavirus outbreak?

Biomarkers of biological age as predictors of COVID-19 disease severity

Protein Coding and Long Noncoding RNA (lncRNA) Transcriptional Landscape in SARS-CoV-2 Infected Bronchial Epithelial Cells Highlight a Role for Interferon and Inflammatory Response

Computational and Transcriptome Analyses Revealed Preferential Induction of Chemotaxis and Lipid Synthesis by SARS-CoV-2

Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis

Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time

Metabolomics-Based Discovery of Molecular Signatures for Triple Negative Breast Cancer in Asian Female Population

Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis

Prognostic factors for severe acute respiratory syndrome: a clinical analysis of 165 cases

The association between severe COVID-19 and low platelet count: evidence from 31 observational studies involving 7613 participants

T-Cell Subset Counts in Peripheral Blood Can Be Used as Discriminatory Biomarkers for Diagnosis and Severity Prediction of Coronavirus Disease

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine

Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease

Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19

D-dimer antigen: current concepts and future prospects

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study

Emerging roles of lncRNA in cancer and therapeutic opportunities

Annotation of long non-coding RNAs expressed in collaborative cross founder mice in response to respiratory virus infection reveals a new class of interferon-stimulated transcripts

Long noncoding RNA MALAT1 releases epigenetic silencing of HIV-1 replication by displacing the polycomb repressive complex 2 from binding to the LTR promoter

The lncRNA Neat1 promotes activation of inflammasomes in macrophages

Study of COVID-19 pandemic in London (UK) from urban context

Covid-19 vaccine: First person receives Pfizer jab in UK

Large-Scale Multi-omic Analysis of COVID-19 Severity

Transcriptomic Analyses Revealed Systemic Alterations in Gene Expression in Circulation and Tumor Microenvironment of Colorectal Cancer Patients. Cancers (Basel)

Near-optimal probabilistic RNA-seq quantification

Single-cell analysis of mixed-lineage states leading to a binary cell fate choice

Ion channel inhibition against COVID-19: A novel target for clinical investigation

The SARS-CoV Fusion Peptide Forms an Extended Bipartite Fusion Platform that Perturbs Membrane Order in a Calcium-Dependent Manner

Ca(2+) Ions Promote Fusion of Middle East Respiratory Syndrome Coronavirus with Host Cells and Increase Infectivity

SARS-CoV fusion peptides induce membrane surface ordering and curvature

Amiodarone alters late endosomes and inhibits SARS coronavirus infection at a post-endosomal level

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirusinduced lung injury

SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS

COVID-19 and cardiovascular consequences: Is the endothelial dysfunction the hardest challenge?

Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents

Functional exhaustion of antiviral lymphocytes in COVID-19 patients

A single-cell atlas of the peripheral immune response in patients with severe COVID-19

Natural killer cell immunotypes related to COVID-19 disease severity

COVID-19: consider cytokine storm syndromes and immunosuppression

Emerging role of IL-6 and NLRP3 inflammasome as potential therapeutic targets to combat COVID-19: Role of lncRNAs in cytokine storm modulation

Prognostic value of long non-coding RNAs in triple negative breast cancer: A PRISMA-compliant meta-analysis

Regulation of a long noncoding RNA MALAT1 by aryl hydrocarbon receptor in pancreatic cancer cells and tissues

Constitutive Interferon Attenuates RIPK1/3-Mediated Cytokine Translation

The long non-coding RNA MALAT1 is increased in renal ischemia-reperfusion injury and inhibits hypoxia-induced inflammation